S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
The Next Big Crisis Is Here (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
The Next Big Crisis Is Here (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
The Next Big Crisis Is Here (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
The Next Big Crisis Is Here (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
NASDAQ:OBSV

ObsEva - OBSV Stock Forecast, Price & News

$0.21
+0.01 (+4.94%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.20
▼
$0.21
50-Day Range
$0.14
▼
$0.21
52-Week Range
$0.13
▼
$2.14
Volume
840,228 shs
Average Volume
498,066 shs
Market Capitalization
$16.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40

ObsEva MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
3,851.1% Upside
$8.40 Price Target
Short Interest
Healthy
2.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of ObsEva in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.23) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

522nd out of 1,054 stocks

Pharmaceutical Preparations Industry

259th out of 517 stocks

See Top Rated MarketRank™ Stocks Here

OBSV stock logo

About ObsEva (NASDAQ:OBSV) Stock

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

January 29, 2023 | americanbankingnews.com
Brokerages Set ObsEva SA (NASDAQ:OBSV) PT at $8.33
January 21, 2023 | americanbankingnews.com
ObsEva (NASDAQ:OBSV) Receives New Coverage from Analysts at StockNews.com
January 29, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 12, 2023 | uk.finance.yahoo.com
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 19, 2022 | finance.yahoo.com
ObsEva Announces Dismissal of Moratorium Proceedings
December 14, 2022 | finance.yahoo.com
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 1, 2022 | finance.yahoo.com
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
December 1, 2022 | finance.yahoo.com
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
October 27, 2022 | finance.yahoo.com
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 16, 2022 | finance.yahoo.com
ObsEva SA (OBSV)
October 14, 2022 | markets.businessinsider.com
ObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasiban
October 13, 2022 | finance.yahoo.com
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo Finance
October 13, 2022 | benzinga.com
ObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - Benzinga
October 13, 2022 | globenewswire.com
ObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswire
October 13, 2022 | finance.yahoo.com
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
October 6, 2022 | reuters.com
OBSV.PH - Obseva SA | Stock Price & Latest News | Reuters
September 15, 2022 | baystreet.ca
ObsEva Flat on Restructuring Initiatives - Baystreet.ca
September 13, 2022 | finance.yahoo.com
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
September 13, 2022 | globenewswire.com
ObsEva Announces Progress on Restructuring Initiatives - GlobeNewswire
September 11, 2022 | reuters.com
OBSV.O - Obseva SA | Stock Price & Latest News | Reuters
September 10, 2022 | reuters.com
OBSV.N - Obseva SA | Stock Price & Latest News | Reuters
September 7, 2022 | finance.yahoo.com
This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'
August 31, 2022 | streetinsider.com
Hot Penny Stocks For Your Buy List in September? 3 to Watch - StreetInsider.com
August 31, 2022 | uk.investing.com
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know By Benzinga - Investing.com UK
August 25, 2022 | businesswire.com
Global Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs - OXO-001 (Oxolife) & Nolasiban (ObsEva) - ResearchAndMarkets.com - Business Wire
August 23, 2022 | seekingalpha.com
ObsEva stock dips on Nasdaq non-compliance notice - Seeking Alpha
See More Headlines
Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Company Calendar

Last Earnings
12/01/2022
Today
1/28/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBSV
CUSIP
N/A
CIK
1685316
Web
www.obseva.com
Phone
(122) 552-3840
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+3,851.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,380,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-416.36%
Return on Assets
-92.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.61
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$20.11 million
Price / Sales
0.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
0.52

Miscellaneous

Outstanding Shares
77,970,000
Free Float
N/A
Market Cap
$16.58 million
Optionable
Not Optionable
Beta
0.49

Key Executives

  • Brian O'Callaghan
    Chief Executive Officer & Director
  • William M. Brown
    Chief Financial Officer
  • Brandi Howard
    Chief Clinical Officer
  • Elke Bestel
    VP, Head-Drug Safety & Pharmacovigilance
  • Luigi Marro
    Chief Transformation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













OBSV Stock - Frequently Asked Questions

Should I buy or sell ObsEva stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OBSV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares.
View OBSV analyst ratings or view top-rated stocks.

What is ObsEva's stock price forecast for 2023?

5 equities research analysts have issued twelve-month price objectives for ObsEva's shares. Their OBSV share price forecasts range from $1.00 to $12.00. On average, they anticipate the company's stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 3,851.1% from the stock's current price.
View analysts price targets for OBSV or view top-rated stocks among Wall Street analysts.

How have OBSV shares performed in 2023?

ObsEva's stock was trading at $0.1450 at the beginning of the year. Since then, OBSV stock has increased by 46.6% and is now trading at $0.2126.
View the best growth stocks for 2023 here.

Are investors shorting ObsEva?

ObsEva saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 1,050,000 shares, a drop of 37.1% from the December 31st total of 1,670,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 2.5% of the company's shares are short sold.
View ObsEva's Short Interest.

When is ObsEva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our OBSV earnings forecast.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, December, 1st. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $0.21.

How much money does ObsEva make?

ObsEva (NASDAQ:OBSV) has a market capitalization of $16.58 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.

This page (NASDAQ:OBSV) was last updated on 1/29/2023 by MarketBeat.com Staff